NCT03026062

Who might be able to join this trial:

• You are 18 years of age or older.
• You are able to carry out normal daily activities, or have only minor limitations due to your illness (confirm with trial site).
• Your blood counts and organ function (including blood cells, liver, and kidneys) are within acceptable levels based on recent lab tests.
• You are either not able to become pregnant (for example, due to menopause, hysterectomy, or surgical sterilization), or you have a negative pregnancy test at the start of the study.
• You are willing and able to attend all required visits, treatments, and procedures, including tissue biopsies, for the full duration of the study.
• You have been diagnosed with recurrent high-grade ovarian, peritoneal, or fallopian tube cancer of a specific type called "clear cell," or a mixed type that includes a clear cell component — confirmed by review at MD Anderson Cancer Center.
• You may also be eligible if you have recurrent uterine serous cancer with a specific gene change called a PPP2R1A mutation (or a related mutation approved by the study doctor), confirmed by approved genetic testing.
• Your cancer has come back or continued to grow during or within 6 months of platinum-based chemotherapy (this does not apply to uterine serous cancer patients, but they must have received at least one prior platinum-based treatment).
• You have at least one measurable tumor that can be clearly measured on a scan or imaging, and your most recent imaging was done within 4 weeks of starting treatment.
• You have signed a written consent form agreeing to take part in the study.

Who may not be able to join:

• You are involved in planning or running this study.
• You have previously been enrolled in this same study.
• You have taken part in another clinical trial using an experimental treatment within the past 28 days.
• You have previously been treated with certain immunotherapy drugs, including PD-1 or PD-L1 inhibitors (such as Durvalumab), CTLA-4 inhibitors (such as Tremelimumab), or adoptive T cell therapy.
• You have had another cancer in the past, unless it was treated successfully with no signs of return for at least 5 years, or it was a minor skin cancer or pre-cancerous condition that was fully treated.
• You received cancer treatment (such as chemotherapy, immunotherapy, or targeted therapy) within the past 28 days (or longer for certain specific treatments — confirm with trial site).
• You have a heart rhythm abnormality of a specific type detected on an ECG (electrocardiogram) test (confirm with trial site).
• You have used medications that suppress your immune system within the past 28 days, except for low-dose steroids or inhaled/nasal steroid sprays.
• You still have side effects from previous cancer treatment that have not fully resolved, except for hair loss.
• You previously had a severe (grade 3 or higher) immune-related reaction from immunotherapy, or you still have unresolved immune-related side effects.
• You have or have had an autoimmune disease (where the immune system attacks the body) in the past 2 years — though some conditions like vitiligo or mild psoriasis not needing treatment may be acceptable.
• You have or have had inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
• You have a history of a condition where your immune system does not work properly from birth (primary immunodeficiency).
• You have received an organ transplant from another person.
• You have had a known allergic reaction to Durvalumab, Tremelimumab, or any of their ingredients.
• You have an uncontrolled ongoing illness, active infection, uncontrolled heart condition, uncontrolled high blood pressure, active hepatitis B, hepatitis C, HIV, or a mental health condition that would affect your ability to participate safely.
• You have a known history of tuberculosis.
• Your cancer has spread to the fluid around the brain or spinal cord, or to the brain itself.
• You have a bowel blockage that has not been resolved.
• You have received a live vaccine within 30 days before starting the study or within 30 days of receiving the study drugs.
• You are pregnant, breastfeeding, or able to become pregnant and are not willing or able to use